255 related articles for article (PubMed ID: 19648825)
1. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer.
Kashihara M; Azuma K; Kawahara A; Basaki Y; Hattori S; Yanagawa T; Terazaki Y; Takamori S; Shirouzu K; Aizawa H; Nakano K; Kage M; Kuwano M; Ono M
J Thorac Oncol; 2009 Sep; 4(9):1066-74. PubMed ID: 19648825
[TBL] [Abstract][Full Text] [Related]
2. Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer.
Hyogotani A; Ito K; Yoshida K; Izumi H; Kohno K; Amano J
Clin Lung Cancer; 2012 Sep; 13(5):375-84. PubMed ID: 22284440
[TBL] [Abstract][Full Text] [Related]
3. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
[TBL] [Abstract][Full Text] [Related]
4. Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer.
Nishio S; Ushijima K; Yamaguchi T; Sasajima Y; Tsuda H; Kasamatsu T; Kage M; Ono M; Kuwano M; Kamura T
Gynecol Oncol; 2014 Mar; 132(3):703-8. PubMed ID: 24486603
[TBL] [Abstract][Full Text] [Related]
5. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
6. Y-box-binding protein-1 expression is not correlated with p53 expression but with proliferating cell nuclear antigen expression in non-small cell lung cancer.
Yoshimatsu T; Uramoto H; Oyama T; Yashima Y; Gu C; Morita M; Sugio K; Kohno K; Yasumoto K
Anticancer Res; 2005; 25(5):3437-43. PubMed ID: 16101161
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.
Cappuzzo F; Gregorc V; Rossi E; Cancellieri A; Magrini E; Paties CT; Ceresoli G; Lombardo L; Bartolini S; Calandri C; de Rosa M; Villa E; Crino L
J Clin Oncol; 2003 Jul; 21(14):2658-63. PubMed ID: 12860941
[TBL] [Abstract][Full Text] [Related]
8. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer.
Shibahara K; Sugio K; Osaki T; Uchiumi T; Maehara Y; Kohno K; Yasumoto K; Sugimachi K; Kuwano M
Clin Cancer Res; 2001 Oct; 7(10):3151-5. PubMed ID: 11595709
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.
Cappuzzo F; Ligorio C; Jänne PA; Toschi L; Rossi E; Trisolini R; Paioli D; Holmes AJ; Magrini E; Finocchiaro G; Bartolini S; Cancellieri A; Ciardiello F; Patelli M; Crino L; Varella-Garcia M
J Clin Oncol; 2007 Jun; 25(16):2248-55. PubMed ID: 17538169
[TBL] [Abstract][Full Text] [Related]
10. Nuclear YB-1 expression as a negative prognostic marker in nonsmall cell lung cancer.
Gessner C; Woischwill C; Schumacher A; Liebers U; Kuhn H; Stiehl P; Jürchott K; Royer HD; Witt C; Wolff G
Eur Respir J; 2004 Jan; 23(1):14-9. PubMed ID: 14738225
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.
Al-Saad S; Al-Shibli K; Donnem T; Andersen S; Bremnes RM; Busund LT
J Thorac Oncol; 2010 Oct; 5(10):1536-43. PubMed ID: 20802349
[TBL] [Abstract][Full Text] [Related]
12. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
Tiseo M; Rossi G; Capelletti M; Sartori G; Spiritelli E; Marchioni A; Bozzetti C; De Palma G; Lagrasta C; Campanini N; Camisa R; Boni L; Franciosi V; Rindi G; Ardizzoni A
Lung Cancer; 2010 Mar; 67(3):355-60. PubMed ID: 19473722
[TBL] [Abstract][Full Text] [Related]
13. Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome.
Onn A; Choe DH; Herbst RS; Correa AM; Munden RF; Truong MT; Vaporciyan AA; Isobe T; Gilcrease MZ; Marom EM
Radiology; 2005 Oct; 237(1):342-7. PubMed ID: 16183941
[TBL] [Abstract][Full Text] [Related]
14. The close correlation between 8-hydroxy-2'-deoxyguanosine and epidermal growth factor receptor activating mutation in non-small cell lung cancer.
Kawahara A; Azuma K; Hattori S; Nakashima K; Basaki Y; Akiba J; Takamori S; Aizawa H; Yanagawa T; Izumi H; Kohno K; Kono S; Kage M; Kuwano M; Ono M
Hum Pathol; 2010 Jul; 41(7):951-9. PubMed ID: 20236686
[TBL] [Abstract][Full Text] [Related]
15. NDRG1/Cap43/Drg-1 may predict tumor angiogenesis and poor outcome in patients with lung cancer.
Azuma K; Kawahara A; Hattori S; Taira T; Tsurutani J; Watari K; Shibata T; Murakami Y; Takamori S; Ono M; Izumi H; Kage M; Yanagawa T; Nakagawa K; Hoshino T; Kuwano M
J Thorac Oncol; 2012 May; 7(5):779-89. PubMed ID: 22481237
[TBL] [Abstract][Full Text] [Related]
16. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.
Cappuzzo F; Toschi L; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Cancellieri A; Magrini E; Bemis L; Franklin WA; Crino L; Bunn PA; Hirsch FR; Varella-Garcia M
Br J Cancer; 2005 Dec; 93(12):1334-40. PubMed ID: 16288303
[TBL] [Abstract][Full Text] [Related]
17. Expression of Y box-binding protein-1 correlates with DNA topoisomerase IIalpha and proliferating cell nuclear antigen expression in lung cancer.
Gu C; Oyama T; Osaki T; Kohno K; Yasumoto K
Anticancer Res; 2001; 21(4A):2357-62. PubMed ID: 11724293
[TBL] [Abstract][Full Text] [Related]
18. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer?
Noberasco C; De Pas T; Curigliano G; Manzoni S; Dodaro L; Pelosi G; Spaggiari L; De Braud F
J Clin Oncol; 2005 Feb; 23(4):921-2; author reply 922. PubMed ID: 15681541
[No Abstract] [Full Text] [Related]
20. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE
Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]